The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: a nested case control study

BACKGROUND: In March 2020, the US Food and Drug Administration decided that the dangers related to neuropsychiatric events (NPEs) of montelukast, one of the leukotriene modifying agents (LTMAs), should be communicated through ‘boxed warning’. In case of NPEs, the prevalence has been the highest in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Sang Oh, Min, Kyung Hyun, Kim, Hyun Jeong, Kim, Tae Hyeok, Kim, Woorim, Lee, Kyung Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972201/
https://www.ncbi.nlm.nih.gov/pubmed/33731203
http://dx.doi.org/10.1186/s40733-021-00070-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972201/
https://www.ncbi.nlm.nih.gov/pubmed/33731203
http://dx.doi.org/10.1186/s40733-021-00070-4

Ejemplares similares